Daiichi
Daiichi Sankyo rocked by further job losses
December 9, 2015Manufacturing and Production Daiichi, Daiichi Sankyo
The Japanese pharma firm Daiichi Sankyo is to close an antibody-producing subsidiary in Germany, as the company continues to cut …
Daiichi sheds more US jobs as generic losses take their toll
October 20, 2015Daiichi, Daiichi Sankyo, generic competition, generics, job losses, patent cliff, patents, redundancies
The Japan-based drugmaker Daiichi Sankyo is to cut up to 1,200 jobs – or about half its workforce – in …
Daiichi scores another NICE nod for Lixiana
August 12, 2015Sales and Marketing Daichii Sankyo, Daiichi, Lixiana, atrial fibrillation, edoxaban
NICE has recommended in draft guidance the anti-blood clotting drug Daiichi Sankyo’s Lixiana for preventing stroke and blood clots in …
NICE recommends Daiichi’s Lixiana for blood clots
July 13, 2015Sales and Marketing DVT, Daiichi, Daiichi Sankyo, Lixiana, NICE, NOACs, VTE, anticoagulant, blood clots, edoxaban, novel anticoagulant. PE
Daiichi Sankyo has won a speedy approval from NICE, after the NHS guidance body approved its newly-launched blood clotting drug …
Sun Pharma sacks 18 Ranbaxy executives
June 19, 2015Manufacturing and Production, Sales and Marketing Daiichi, India, Ranbaxy, Sun Pharma, brett wells
Sun Pharma has asked 18 executives to leave the company who were previously a part of Ranbaxy, the firm it …
Eisai cuts 25% of US staff
April 10, 2015Medical Communications, Research and Development, Sales and Marketing Daiichi, Eisai, US, cuts, layoffs, reorganisation, staff
Eisai’s US business is offloading around 200 jobs as part of some restructuring to create a more ‘efficient and focussed …
AstraZeneca and Daiichi team up for constipation drug
March 19, 2015Sales and Marketing AstraZeneca, Daiichi, Movantik, constipation, naloxegol, oic
AstraZeneca and Daiichi Sankyo have signed a deal worth around $825 million to jointly commercialise constipation drug Movantik in the …
Daiichi’s lung cancer drug progresses to phase III
August 5, 2010Research and Development Daiichi, arq 197, arqule, lung cancer, phase III
Daiichi Sankyo and biotech firm Arqule are to move their lung cancer treatment ARQ 197 into phase III trials. The …
Efient launched in the UK
April 9, 2009Research and Development, Sales and Marketing Daiichi, Effient, lilly
Lilly and Daiichi Sankyo's blood-thinning drug Efient has been launched in the UK for heart attack patients, taking on blockbuster …
Europe approves Lilly’s Plavix rival
February 25, 2009Research and Development, Sales and Marketing Daiichi, Effient, lilly
Lilly and Daiichi Sankyo have won European approval for their blood-thinning drug Efient, which will go up against established blockbuster …
Daiichi Sankyo sets up Ireland operations
November 27, 2008Sales and Marketing Daiichi, Ireland
Japanese company Daiichi Sankyo is continuing its expansion in Europe with the launch of operations in Ireland.The new subsidiary's headquarters …
